Unknown

Dataset Information

0

Novel cAMP binding protein-BP (CREBBP) mutation in a girl with Rubinstein-Taybi syndrome, GH deficiency, Arnold Chiari malformation and pituitary hypoplasia.


ABSTRACT: BACKGROUND: Rubinstein-Taybi syndrome (RTS) is a rare autosomal dominant disorder (prevalence 1:125,000) characterised by broad thumbs and halluces, facial dysmorphism, psychomotor development delay, skeletal defects, abnormalities in the posterior fossa and short stature. The known genetic causes are point mutations or deletions of the cAMP-response element binding protein-BP (CREBBP) (50-60% of the cases) and of the homologous gene E1A-binding protein (EP300) (5%). CASE PRESENTATION: We describe, for the first time in literature, a RTS Caucasian girl, 14-year-old, with growth hormone (GH) deficiency, pituitary hypoplasia, Arnold Chiari malformation type 1, double syringomyelic cavity and a novel CREBBP mutation (c.3546insCC). CONCLUSION: We hypothesize that CREBBP mutation we have identified in this patient could be responsible also for RTS atypical features as GH deficiency and pituitary hypoplasia.

SUBMITTER: Marzuillo P 

PROVIDER: S-EPMC3598247 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel cAMP binding protein-BP (CREBBP) mutation in a girl with Rubinstein-Taybi syndrome, GH deficiency, Arnold Chiari malformation and pituitary hypoplasia.

Marzuillo Pierluigi P   Grandone Anna A   Coppola Ruggero R   Cozzolino Domenico D   Festa Adalgisa A   Messa Federica F   Luongo Caterina C   Del Giudice Emanuele Miraglia EM   Perrone Laura L  

BMC medical genetics 20130223


<h4>Background</h4>Rubinstein-Taybi syndrome (RTS) is a rare autosomal dominant disorder (prevalence 1:125,000) characterised by broad thumbs and halluces, facial dysmorphism, psychomotor development delay, skeletal defects, abnormalities in the posterior fossa and short stature. The known genetic causes are point mutations or deletions of the cAMP-response element binding protein-BP (CREBBP) (50-60% of the cases) and of the homologous gene E1A-binding protein (EP300) (5%).<h4>Case presentation<  ...[more]

Similar Datasets

| S-EPMC1626071 | biostudies-literature
| S-EPMC5911335 | biostudies-literature
| S-EPMC4989203 | biostudies-literature
| S-EPMC8017357 | biostudies-literature
| S-EPMC2987354 | biostudies-literature
| S-EPMC4707034 | biostudies-literature
| S-EPMC3039495 | biostudies-literature
| S-EPMC7389331 | biostudies-literature
| S-EPMC3864413 | biostudies-other
| S-EPMC3065314 | biostudies-other